A $4 million missile against a $2,000 drone is a losing equation. Cambridge Aerospace closed $300M at a $3.4B valuation to manufacture Skyhammer interceptors at 2,500 a month by March 2027, betting unit cost — not payload sophistication — ends the asymmetry.
In January 2026, Quali Drone and RWE inspected a spinning offshore turbine's blades for the first time — no shutdown, no rope access. Perceptual Robotics raised £4M to scale it; Percepto launched an AI platform for energy assets. A $650M market compounds 22.7% toward $3.3B by 2034.
Microbes on a cathode can turn surplus wind power and CO2 into acetate, bioplastics and single-cell protein — if the electrons arrive on a schedule. A Stanford run held 2 mM/h under intermittency; a 2026 review says the ceiling has moved from biology to reactor and grid design.
Neros raised a $250M Series C at a $2.5B post-money valuation, tripling its value, and committed to one million drones a year by 2028. Two former drone racers turned a supply-chain bet into Sequoia and Thiel backing. Here is what the scale promise means for the small-drone market.
First-party LLM API list prices, early August 2026: floor $0.14 per million input tokens (DeepSeek V4 Flash), ceiling $30.00 (GPT-5.5-pro). The price war moved to cache reads and cost-per-task is displacing cost-per-token; Anthropic cancelled a Sonnet 5 increase on August 11.
The ISS National Lab chose eight startups for the 2026 Orbital Edge Accelerator, split into a Sentinel Track for dual-use space infrastructure and a Disrupt Track for in-space manufacturing and biology. Each gets up to $750K in private capital and a flight test on the ISS.
The reversible solid oxide fuel cell startup booked a 1 GW joint venture with Sabanci Renewables for AI data center power, on top of April's Meta reservation. What has to go right for the chemistry to keep the promise.
A 13-person startup raised $152 million to run a global Phase 3 in HHT, a rare vascular disorder with no approved therapy. The data that could make engasertib the first approved treatment, and the risks that remain.